UGT2B17基因缺失与前列腺癌风险无关。
The UGT2B17 gene deletion is not associated with prostate cancer risk.
作者信息
Olsson Mats, Lindström Sara, Häggkvist Benjamin, Adami Hans-Olov, Bälter Katarina, Stattin Pär, Ask Birgitta, Rane Anders, Ekström Lena, Grönberg Henrik
机构信息
Department of Urology, Karolinska University Hospital, Stockholm, Sweden.
出版信息
Prostate. 2008 Apr 1;68(5):571-5. doi: 10.1002/pros.20700.
BACKGROUND
Deletion polymorphism of the UDP-glucuronosyltransferase 2B17 (UGT2B17) gene has been associated with an increased prostate cancer risk in two previous independent studies. Here we determine the risk in a large-scale population-based case-control study.
METHODS
Genotyping was conducted with a 5'-nuclease activity assay to distinguish those with one or two UGT2B17 gene copies (ins/del and ins/ins) from individuals homozygous for the deletion (del/del) allele.
RESULTS
In contrast to previous findings, no association between the UGT2B17 deletion polymorphism and prostate cancer risk was found. Furthermore the UGT2B17 gene deletion did not affect the risk for prostate cancer specific death.
CONCLUSION
The UGT2B17 deletion polymorphism does not play a major role in prostate cancer susceptibility as previously indicated.
背景
在之前两项独立研究中，尿苷二磷酸葡萄糖醛酸基转移酶2B17（UGT2B17）基因的缺失多态性与前列腺癌风险增加相关。在此，我们在一项大规模基于人群的病例对照研究中确定其风险。
方法
采用5'-核酸酶活性测定法进行基因分型，以区分具有一个或两个UGT2B17基因拷贝（插入/缺失和插入/插入）的个体与缺失等位基因纯合子（缺失/缺失）个体。
结果
与之前的研究结果相反，未发现UGT2B17缺失多态性与前列腺癌风险之间存在关联。此外，UGT2B17基因缺失并不影响前列腺癌特异性死亡风险。
结论
UGT2B17缺失多态性并不像之前所表明的那样在前列腺癌易感性中起主要作用。
Zotero 插件